EUCTR2012-002639-27-ES进行中（未招募）1 期
A phase II, multicentre study to evaluate the long-term safety and efficacy of MT-1303 in subjects with relapsing-remitting multiple sclerosis who have completed the MT-1303-E04 study
Mitsubishi Tanabe Pharma Corporation (MTPC)0 个研究点目标入组 400 人开始时间: 2013年1月9日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Completion of the 24-week Treatment Period in MT-1303-E04 as per protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 400
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Permanent discontinuation of study medication prior to the End of Treatment (EOT) Visit in MT-1303-E04
- •2. Newly diagnosed diabetes mellitus during MT-1303-E04
研究者
相似试验
进行中（未招募）
1 期
A study to assess long-term safety and effectiveness of MT-1303 in subjects who completed the MT-1303-E04 study.EUCTR2012-002639-27-PLMitsubishi Tanabe Pharma Corporation (MTPC)400
进行中（未招募）
1 期
A study to assess long-term safety and effectiveness of MT-1303 in subjects who completed the MT-1303-E04 study.Relapsing-remitting multiple sclerosis (RRMS)MedDRA version: 14.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-002639-27-HUMitsubishi Tanabe Pharma Corporation (MTPC)400
进行中（未招募）
1 期
A study to assess long-term safety and effectiveness of MT-1303 in subjects who completed the MT-1303-E04 study.EUCTR2012-002639-27-LTMitsubishi Tanabe Pharma Corporation (MTPC)400
进行中（未招募）
1 期
A study to assess long-term safety and effectiveness of MT-1303 in subjects who completed the MT-1303-E04 study.Relapsing-remitting multiple sclerosis (RRMS)MedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-002639-27-CZMitsubishi Tanabe Pharma Corporation (MTPC)400
进行中（未招募）
1 期
A phase II, multicentre study to evaluate the long-term safety and efficacyof MT-1303 in subjects with relapsing-remitting multiple sclerosis whohave completed the MT-1303-E04 studyRelapsing-remitting multiple sclerosis (RRMS)EUCTR2012-002639-27-ITMITSUBISHI TANABE PHARMA CORPORATIO367